Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : The Thread Formerly Known as No Rest For The Wicked -- Ignore unavailable to you. Want to Upgrade?

To: MARK C. who wrote (33700)	4/28/1999 2:30:00 PM
From: kathyh	Read Replies (6) \| Respond to of 90042

i just let some guy have it on the sunw thread... couldn't help myself... Message 9198898 think he might beat me up?? kathy :))

To: MARK C. who wrote (33700)	4/28/1999 2:31:00 PM
From: luther yow	Respond to of 90042

Just bought pfe for a turtle profit, I also believe around 3or 4 spread. Have been wrong before but downside risk is small.imho Luther

To: MARK C. who wrote (33700)	4/28/1999 2:36:00 PM
From: HeatherN	Read Replies (4) \| Respond to of 90042

Mark C., Although PFE is a very good company, I wouldn't rely too heavily on Celebrex to bring as much to the table long term for them. There is a sulfa allergy problem as well as some recent GI side effects seen. It is a useful drug, but the profile of MRK's Vioxx is much more favorable. Vioxx is being recommended for approval for arthritis and other types of pain, whereas Celebrex is approved only for arthritis. I prescribe pain meds on a daily basis for 30-40 patients per day. Celebrex is OK but it's market share will take a big tumble when Vioxx comes out. PFE does have a great R& D budget to keep other drugs coming through the pipeline.jmho